<DOC>
	<DOC>NCT03102203</DOC>
	<brief_summary>To evaluate the efficacy of multi-modality magnetic resonance quantitative parameters in evaluating the treatment effects of high-grade gliomas, and to provide new biomarkers for the establishment of new diagnostic criteria for the identification of true and pseudoprogression of high-grade gliomas.</brief_summary>
	<brief_title>Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>1. Patients with highgrade gliomas confirmed by pathology and have not been treated with concurrent chemoradiotherapy; 2. Written informed consent is obtained. 1. Patients not suitable for enhanced MRI scanning of patients; 2. Patients who have not finished followup concurrent chemoradiotherapy or MR scanning.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>